Biomarin Pharmaceut (BMRN) 100.25 $BMRN
Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:51PM CDT
Pfizer (PFE), which is set to report second-quarter 2016 results on Aug 2, had delivered a positive earnings surprise of 21.82% last quarter. Will it beat estimates again?
BMRN: 100.25 (+0.83), PFE: 37.31 (+0.42), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
SmarTrend Watching for Potential Pullback in Shares of BioMarin Pharmaceutical After 1.14% Gain
Comtex SmarTrend(R) - Thu Jul 28, 12:30PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $96.64 to a high of $99.50. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $98.71 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 100.25 (+0.83)
Covered Call reports for GoPro, American Airlines, BioMarin Pharmaceutical, Caterpillar Inc. and TASER International include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAL, BMRN, CAT, GPRO, and TASR.
GPRO: 12.94 (+0.30), BMRN: 100.25 (+0.83), AAL: 35.60 (+0.10), CAT: 81.95 (-0.81), TASR: 29.16 (+0.20)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 6.6%
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:15AM CDT
BioMarin Pharmaceutical Inc. (BMRN) shares rose almost 7% in the last trading session.
BMRN: 100.25 (+0.83), ANIP: 61.06 (+0.46)
FDA Accepts BLA for BioMarin's Cerliponase Alfa for CLN2 Disease, Form of Batten Disease
GlobeNewswire - Wed Jul 27, 5:01PM CDT
Potential First Treatment for Fatal, Rare, Brain Disease in Children
BMRN: 100.25 (+0.83)
BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress
GlobeNewswire - Wed Jul 27, 1:30PM CDT
6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7 patient above 10%
BMRN: 100.25 (+0.83)
Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 6:24AM CDT
Merck (MRK) had posted a positive earnings surprise in Q1. Will the stock deliver a positive surprise again this quarter?
BMRN: 100.25 (+0.83), MRK: 58.66 (unch), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)
ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 5:58AM CDT
Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
BMRN: 100.25 (+0.83), INCY: 90.00 (-0.21), AMGN: 174.16 (+2.13), ARIA: 9.71 (+0.20)
Micron, JC Penney, Seagate Technology, Amazon.com, and BioMarin Pharmaceutical and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Jul 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, BMRN, JCP, MU, and STX.
MU: 13.56 (-0.18), AMZN: 767.74 (+8.93), BMRN: 100.25 (+0.83), STX: 32.43 (+0.40), JCP: 9.71 (+0.05)
BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 5.58%
Comtex SmarTrend(R) - Fri Jul 15, 12:21PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $89.19 to a high of $94.00. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $89.98 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 100.25 (+0.83)
New Reports on Recent Market Movers BioMarin Pharmaceutical, SemiLEDs, Fitbit and EZCORP
ACCESSWIRE - Mon Jul 11, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / July 11, 2016 / Despite positive falling jobless claims, U.S. markets slumped Thursday alongside oil prices. The Dow Jones Industrial Average fell 0.14 percent to close at 17,892.89, while the S&P 500 Index declined 0.09 percent to close at 2,097.70. Oil prices declined 4.8 percent to settle near two-month lows after data showed a smaller-than-expected decline in inventories. The Energy Information Administration reported U.S. crude stockpiles decreased by 2.2 million barrels to 524.4 million for the week ended July 1st. Analysts had forecasted a decline of 2.3 million barrels, according to a poll by Reuters. On Wednesday, the American Petroleum Institute reported a decline of 6.7 million barrels.
FIT: 13.69 (+0.03), BMRN: 100.25 (+0.83), EZPW: 9.04 (-0.02), LEDS: 5.49 (-0.11)
Catabasis' DMD Drug in Phase II Open-Label Extension Study
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:28AM CDT
Catabasis (CATB) initiated an open-label extension for the phase II portion (Part
of its MoveDMD study on edasalonexent for the treatment of DMD.
BMRN: 100.25 (+0.83), CATB: 4.08 (+0.21), GWPH: 96.11 (+1.79), SRPT: 25.91 (+0.63)
BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 7.81%
Comtex SmarTrend(R) - Thu Jul 07, 11:57AM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $86.14 to a high of $90.20. Yesterday, the shares gained 7.8%, which took the trading range above the 3-day high of $81.67 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 100.25 (+0.83)
BioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL
GlobeNewswire - Mon Jun 20, 3:35PM CDT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII International Congress of the World Federation of Hemophilia. The presentation will report interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia. BMN 270 has received orphan drug designation from the European Commission and U.S. Food and Drug Administration.
BMRN: 100.25 (+0.83)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 301.83 (+11.90), BMRN: 100.25 (+0.83), ALXN: 133.50 (+4.90), IBB: 294.07 (+4.63), REGN: 434.00 (+8.88)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 301.83 (+11.90), BMRN: 100.25 (+0.83), SRPT: 25.91 (+0.63), ALXN: 133.50 (+4.90), IBB: 294.07 (+4.63), REGN: 434.00 (+8.88)
Conatus (CNAT) May Surprise in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:36PM CDT
Conatus (CNAT), which is set to report second-quarter 2016 results on Aug 3, posted in-line results last quarter. Will the stock pull a surprise this quarter?
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
BioMarin (BMRN) May Beat in Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:04AM CDT
BioMarin (BMRN), which is scheduled to report second-quarter 2016 results on Aug 4, had delivered a positive earnings surprise of 58.82% last quarter.
BMRN: 100.25 (+0.83), CNAT: 2.29 (+0.03), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:51PM CDT
Pfizer (PFE), which is set to report second-quarter 2016 results on Aug 2, had delivered a positive earnings surprise of 21.82% last quarter. Will it beat estimates again?
BMRN: 100.25 (+0.83), PFE: 37.31 (+0.42), ICPT: 169.72 (-3.31), EXEL: 9.27 (+0.09)
SmarTrend Watching for Potential Pullback in Shares of BioMarin Pharmaceutical After 1.14% Gain
Comtex SmarTrend(R) - Thu Jul 28, 12:30PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $96.64 to a high of $99.50. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $98.71 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 100.25 (+0.83)
Covered Call reports for GoPro, American Airlines, BioMarin Pharmaceutical, Caterpillar Inc. and TASER International include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AAL, BMRN, CAT, GPRO, and TASR.
GPRO: 12.94 (+0.30), BMRN: 100.25 (+0.83), AAL: 35.60 (+0.10), CAT: 81.95 (-0.81), TASR: 29.16 (+0.20)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 6.6%
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:15AM CDT
BioMarin Pharmaceutical Inc. (BMRN) shares rose almost 7% in the last trading session.
BMRN: 100.25 (+0.83), ANIP: 61.06 (+0.46)
FDA Accepts BLA for BioMarin's Cerliponase Alfa for CLN2 Disease, Form of Batten Disease
GlobeNewswire - Wed Jul 27, 5:01PM CDT
Potential First Treatment for Fatal, Rare, Brain Disease in Children
BMRN: 100.25 (+0.83)
BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress
GlobeNewswire - Wed Jul 27, 1:30PM CDT
6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7 patient above 10%
BMRN: 100.25 (+0.83)
Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 6:24AM CDT
Merck (MRK) had posted a positive earnings surprise in Q1. Will the stock deliver a positive surprise again this quarter?
BMRN: 100.25 (+0.83), MRK: 58.66 (unch), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)
ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 5:58AM CDT
Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
BMRN: 100.25 (+0.83), INCY: 90.00 (-0.21), AMGN: 174.16 (+2.13), ARIA: 9.71 (+0.20)
Micron, JC Penney, Seagate Technology, Amazon.com, and BioMarin Pharmaceutical and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Jul 19, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMZN, BMRN, JCP, MU, and STX.
MU: 13.56 (-0.18), AMZN: 767.74 (+8.93), BMRN: 100.25 (+0.83), STX: 32.43 (+0.40), JCP: 9.71 (+0.05)
BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 5.58%
Comtex SmarTrend(R) - Fri Jul 15, 12:21PM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $89.19 to a high of $94.00. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $89.98 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 100.25 (+0.83)
New Reports on Recent Market Movers BioMarin Pharmaceutical, SemiLEDs, Fitbit and EZCORP
ACCESSWIRE - Mon Jul 11, 8:15AM CDT
NEW YORK, NY / ACCESSWIRE / July 11, 2016 / Despite positive falling jobless claims, U.S. markets slumped Thursday alongside oil prices. The Dow Jones Industrial Average fell 0.14 percent to close at 17,892.89, while the S&P 500 Index declined 0.09 percent to close at 2,097.70. Oil prices declined 4.8 percent to settle near two-month lows after data showed a smaller-than-expected decline in inventories. The Energy Information Administration reported U.S. crude stockpiles decreased by 2.2 million barrels to 524.4 million for the week ended July 1st. Analysts had forecasted a decline of 2.3 million barrels, according to a poll by Reuters. On Wednesday, the American Petroleum Institute reported a decline of 6.7 million barrels.
FIT: 13.69 (+0.03), BMRN: 100.25 (+0.83), EZPW: 9.04 (-0.02), LEDS: 5.49 (-0.11)
Catabasis' DMD Drug in Phase II Open-Label Extension Study
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:28AM CDT
Catabasis (CATB) initiated an open-label extension for the phase II portion (Part
of its MoveDMD study on edasalonexent for the treatment of DMD. BMRN: 100.25 (+0.83), CATB: 4.08 (+0.21), GWPH: 96.11 (+1.79), SRPT: 25.91 (+0.63)
BioMarin Pharmaceutical Set to Possibly Pullback After Yesterday's Rally of 7.81%
Comtex SmarTrend(R) - Thu Jul 07, 11:57AM CDT
BioMarin Pharmaceutical (NASDAQ:BMRN) traded in a range yesterday that spanned from a low of $86.14 to a high of $90.20. Yesterday, the shares gained 7.8%, which took the trading range above the 3-day high of $81.67 on volume of 4.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BMRN: 100.25 (+0.83)
BioMarin Announces Acceptance of Late Breaking Abstract for BMN 270 at the World Federation of Hemophilia (WFH) 2016 World Congress July 27 in Orlando, FL
GlobeNewswire - Mon Jun 20, 3:35PM CDT
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII International Congress of the World Federation of Hemophilia. The presentation will report interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia. BMN 270 has received orphan drug designation from the European Commission and U.S. Food and Drug Administration.
BMRN: 100.25 (+0.83)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:30AM CDT
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology, Biogen, Alexion Pharma, BioMarin Pharma and Regeneron
BIIB: 301.83 (+11.90), BMRN: 100.25 (+0.83), ALXN: 133.50 (+4.90), IBB: 294.07 (+4.63), REGN: 434.00 (+8.88)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 301.83 (+11.90), BMRN: 100.25 (+0.83), SRPT: 25.91 (+0.63), ALXN: 133.50 (+4.90), IBB: 294.07 (+4.63), REGN: 434.00 (+8.88)
